56 results about "Human coronavirus" patented technology

The invention discloses a primer group and a kit for simultaneously detecting nucleic acids of various respiratory pathogens based on twenty-six PCR (Polymerase Chain Reaction). The kit comprises primer pool freeze-dried powder of influenza A virus (FluA), influenza B virus (FluB), respiratory syncytial virus (RSV), human parainfluenza virus (hPIV), mycoplasma pneumoniae (MP), novel coronavirus (SARS-CoV-2), human respiratory adenovirus (HADV), human respiratory nose / enterovirus (HRV / HEV), bordetella pertussis (BP), human coronavirus (HCoV), human bocavirus (HBoV) and chlamydia pneumoniae (CP), PCR (polymerase chain reaction) freeze-dried powder and a buffer solution. According to the kit, primer system optimization is carried out on various pathogens, brand new primers and probe pools are designed, clinical sensitivity and specificity can be achieved, and meanwhile, the kit is matched with a fully-closed full-automatic detection card box integrating sample treatment and amplification and is suitable for rapid detection of respiratory tract pathogens.

Pan-coronavirus vaccines for inducing efficient, powerful and long-lasting protection against all Coronaviruses infections and diseases, comprising multiple highly conserved large sequences which may comprise one or more conserved B, CD4 and CDS T cell epitopes that help provide multiple targets for the body to develop an immune response for preventing a Coronavirus infection and / or disease. In certain embodiments, the large sequences are conserved proteins or large sequences, e.g., sequences that are highly conserved among human coronaviruses and / or animal coronaviruses (e.g., coronaviruses isolated from animals susceptible to coronavirus infections).

The application discloses an application of baicalin in treating coronavirus infectious diseases. The new application of baicalin is verified through in-vitro cell tests and mouse tests infected with human coronavirus HCoV-229E, the technical scheme is novel, and a curative effect test of baicalin in treating pneumonia caused by HCoV-229E virus infection is carried out, and the results show that baicalin has a certain inhibitory effect on HCoV-229E infected cells in vitro; baicalin shows good drug efficacy in lung index and inhibition rate of pneumonia mice infected with HCoV-229E virus, can reduce the virus load of lung tissue of pneumonia mice infected with HCoV-229E virus, increase the proportion of peripheral blood lymphocytes of mice, and reduce the content of IL-2, IL-10, TNF-alpha and IFN-beta in lung tissue of mice.

An objective of the present invention is to provide a nonpharmaceutical anti-human coronavirus composition that prevents human coronavirus infections, the onset of the infections, or aggravation of symptoms of the infections. The anti-human coronavirus composition according to the present invention includes an exopolysaccharide produced by a lactic acid bacterium in genus Lactobacillus as an active component. The lactic acid bacterium in the genus Lactobacillus may belong to a Lactobacillus delbrueckii species. The lactic acid bacterium in the genus Lactobacillus may specifically be Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 (FERM BP-10741).

The present invention concerns compositions comprising at least one niclosamide compound, such as niclosamide or a pharmaceutically acceptable salt thereof, and at least one permeability enhancer, such as glycerol or dimethylpalmityl-ammonio propanesulfonate (PPS), and their use of such compositions as niclosamide agents. Advantageously, the niclosamide compound is capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 cell membrane in the absence of the permeability enhancer. Compositions, including oral dosage forms, and methods for delivering niclosamide compounds, such as for treatment or prevention of human coronavirus infections, are also provided.

Disclosed are methods for culturing coronavirus particles in early syncytiotrophoblasts (eSTBs). The derived eSTBs are mononucleated or bi-nucleated cells with high ACE2 expression and are not multi-n

The present invention concerns compositions comprising at least one niclosamide compound, such as niclosamide or a pharmaceutically acceptable salt thereof, and at least one permeability enhancer, such as glycerol or dimethylpalmityl-ammonio propanesulfonate (PPS), and their use of such compositions as niclosamide agents. Advantageously, the niclosamide compound is capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 cell membrane in the absence of the permeability enhancer. Compositions, including oral dosage forms, and methods for delivering niclosamide compounds, such as for treatment or prevention of human coronavirus infections, are also provided.

Compound for use in a method of treating a coronavirus infection, wherein the compound comprises Artemether, Atazanavir, Efavirenz, Fosamprenavir or Saquinavir, and wherein the method includes administering to a subject in need of the treatment an effective amount of the compound; wherein the term “compound” is inclusive of pharmaceutically acceptable salts of the compound; and wherein the coronavirus infection is an infection by a human coronavirus (e.g. SARS-CoV-2). Also claimed for use are the same compounds for use in a method of treating a coronavirus infection, or for use in a prophylaxis method to prevent Covid-19 infection. Further claimed, is compounds for use in a method of treating a coronavirus infection, wherein the compounds comprise: (A) Atazanavir, Efavirenz, Fosamprenavir, Saquinavir or Remdesivir (GS-5734); and (B) an antimalarial drug, an anti-hypertensive drug, an immunomodulatory drug, a neuroprotective drug, or an anti-inflammatory drug, each of which is as defined herein; wherein the method includes administering to a subject in need of the treatment or prophylaxis an effective amount of the compounds.

Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and / or hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV-2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.

In one aspect, the present disclosure is directed to a method for preventing or treating a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmunized egg product obtained from an egg-producing animal, thereby preventing or treating coronavirus infection in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to the coronavirus. The present disclosure is also directed to hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen selected from i) a spike (S) protein, an S1 subunit protein, an S2 subunit protein, a receptor binding domain (RBD), and an immunogenic fragment thereof; ii) a nucleocapsid (N) protein, and an immunogenic fragment thereof; iii) a human ACE2 receptor protein, and an immunogenic fragment thereof; and iv) a human coronavirus selected from the group consisting of SARS-CoV, MERS-CoV, SARS-CoV-2, HCoV-HKU1, HCoV-NL63, HCoV-OC43 and HCoV-229E. Methods of preparing the hyperimmunized eggs and egg products are also disclosed.

Compounds, compositions and methods for preventing, treating or curing a coronavirus infection in human subjects or other animal hosts. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1, OC43, and SARS-CoV-2. In another embodiment, the methods are used to treat a patient infected with a Flavivirus, Picornavus, Togavirus, or Bunyavirus.

The present invention belongs to the field of drug therapy, and specifically relates to the use of methyl parahydroxybenzoate and its sodium salt in the preparation of drugs for treating viral infectious diseases. The present invention discloses the use of methyl parahydroxybenzoate, its sodium salt and its inhalation preparation in the treatment of coronavirus infectious diseases. By verifying the new use of methyl parahydroxybenzoate and its sodium salt inhalation solution in a mouse test infected with human coronavirus HCoV-229E, the technical solution has novelty, and an efficacy test of meta-cresol inhalation solution in treating pneumonia caused by HCoV-229E virus infection was conducted. The results showed that methyl parahydroxybenzoate and its sodium salt inhalation solution showed good efficacy in the lung index and inhibition rate of pneumonia mice infected with HCoV-229E virus, and could significantly reduce the mouse lung index.

The invention discloses an application of an eIF2alpha kinase regulator in preparation of an anti-human coronavirus drug. Specifically, the compound provided by the invention has the activity of resisting human coronavirus HCoV-OC43 and / or resisting new coronavirus of human coronavirus. The invention focuses on antiviral host factors, provides a target compound for targeting host eIF2alpha kinase, eIF2alpha phosphorylation and protein synthesis, plays an antiviral role by accurately regulating and controlling host virus interaction, and is beneficial to overcoming virus resistance and obtaining broad-spectrum antiviral activity.

At least one pharmaceutical composition for use in a method of prophylaxis or treatment of COVID wherein the at least one pharmaceutical composition comprises donepezil, rivastigmine or galantamine or one of donepezil, rivastigmine or galantamine combined with one of: Artemether and Lumefantrine; Atazanavir Sulfate; Efavirenz; Fosamprenavir Calcium; Saquinavir; Remdesivir (GS-5734); Digoxin; Memantine; Rivastigmine; Galantamine; Valsartan; Teriflunomide and wherein the method of prophylaxis or treatment of COVID or COVID-19 comprises: providing a subject in need of said prophylaxis or treatment; providing the at least one pharmaceutical composition as defined supra; wherein said components are provided together or separately; wherein said components are administered together or separately; and wherein said components are provided in a pharmaceutically acceptable diluent, adjuvant and / or excipient; and administering a pharmaceutically effective amount of said at least one pharmaceutical composition to said subject; and wherein, in the method, said subject is provided prophylaxis or treatment of COVID and COVID relates to a human coronavirus, mouse hepatitis virus (MHV), or recombinant mouse-adapted SARS-CoV (SARS-CoV MAI 5).

The present invention belongs to the field of pharmaceutical biotechnology, and specifically relates to an application of a compound represented by formula (1) in the preparation of a drug, wherein the drug is a drug for inhibiting coronavirus, preferably, the drug is a drug for treating human coronavirus infection, and the coronavirus is preferably a human alpha coronavirus or a human beta coronavirus.

The application provides a pharmaceutical composition, which comprises an antiviral peptide conjugate, for the treatment or prevention of a condition or disease associated with a coronaviral infection. The coronavirus includes human coronavirus OC43, human coronavirus HKU1, human coronavirus 229E, human coronavirus NL63, Middle East respiratory syndrome-related coronavirus (MERS-CoV), SARS-CoV, SARS-CoV-2, or any variant thereof. The pharmaceutical composition is designed for, inter alia, intranasal administration.

Antimicrobial compositions include a therapeutically effective amount of neem oil, extract of the plant Hypericum spp., polyunsaturated fatty acids (PUFAs), carrageenans, and / or chlorhexidine; and (optionally) in combination with one or more pharmaceutically acceptable carriers, additives, and / or diluents. The antimicrobial compositions are effective in treating or preventing upper respiratory tract infections, preferably upper respiratory tract infections caused by human Coronaviruses and are included within methods of treating or preventing infection of the upper respiratory tract of humans by a microbial pathogen.

The invention discloses a primer probe, a method and application for detecting human coronavirus OC43. The nucleic acid sequence of the primer comprises the sequences as shown in SEQ ID NO. 7 to SEQ ID NO. 8; the nucleic acid sequence of the fluorescent probe comprises a sequence as shown in SEQ ID NO.9. The primer and the fluorescent probe for detecting the human coronavirus OC43 are creatively designed, the human coronavirus OC43 inactivated virus standard substance can be accurately detected by using the primer, the probe and the digital valuing method, the sensitivity is high, and the specificity is strong.

This invention provides a novel small-molecule allosteric protease inhibitor, 10-(4-methylphenyl)-7-phenyl-6,7,8,10-tetrahydro-5H-indeno[1,2-b]quinoline-9,11-dione, which exhibits the highest selectivity index (SI), and shows inhibition against several SARS-CoV-2 variants of concern (VOC) and multiple human coronaviruses including MERS-CoV, SARS-CoV, and HCoV-229E. Not only does it demonstrate antiviral potency against a wide spectrum of coronavirus strains and species, but it also shows drug synergism with nirmatrelvir, which could be used in combination therapy to not only treat coronavirus-caused infections and diseases, but also lower the risk of antiviral resistance.

The present invention relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the present invention relates to the treatment and prevention of human coronavirus 2019-nCoV.

Methods and compositions containing a phorbol ester or derivative of a phorbol ester are provided for prevention and treatment of sudden acute respiratory syndrome (SARS) coronavirus infection, including SARS-COV-2 infection and related COVID-19 disease. Also provided are methods and compositions for preventing and treating acute inflammatory conditions and related pathogenic injuries, including Acute Respiratory Distress Syndrome (ARDS) and cytokine storm syndrome (CSS) seen in severe SARS-COV-2 / COVID-19 cases.

The present invention relates to a drug comprising a polynucleotide for the prevention or treatment of SARS-CoV-2 virus infection, wherein the SARS-CoV-2 virus is not the Wuhan wild type SARS-CoV-2 virus. The present invention relates to a polynucleotide encoding an attenuated human coronavirus or fragment thereof wherein the polynucleotide comprises at least 20 one to termination codons wherein the one to termination codons are: i) codons that are different but synonymous compared to the corresponding codons in the native human coronavirus genome; and ii) a nucleotide different from the termination codon.

The invention discloses a beta-nucleoside compound for inhibiting coronavirus as well as synthesis and application thereof, the compound has a structure as shown in formula 1, # imgabs0 is used for treating human coronavirus in coronaviridae and coronavirus alpha and beta.

The present disclosure generally relates to the fields of virology, infectious diseases, and medicine, and describes compounds, compositions, methods, and kits for treating CoV-mediated diseases such as those caused by SARS-CoV-2, SAR8, or MERS. More specifically, the present disclosure relates to effective inhibitors of coronaviruses, which can treat coronaviruses, including the 2019 novel coronavirus. In one embodiment, the present disclosure provides a new use of WX-671 as an effective inhibitor of coronaviruses and its application in the preparation of a medicament for treating human coronavirus infection. In one embodiment, the present disclosure provides a new use of ABC294640 as an effective inhibitor of coronaviruses and its application in the preparation of a medicament for treating human coronavirus infection.

The invention relates to pharmaceutical product comprising a polynucleotide for use in the prevention or treatment of a SARS-CoV-2 virus infection wherein said SARS-CoV-2 virus is not a Wuhan wild-type SARS-CoV-2 virus. The polynucleotide encodes an attenuated human coronavirus or a fragment thereof, wherein the polynucleotide comprises at least 20 one-to-stop codons, wherein a one-to-stop codon is i) a different but synonymous codon compared to the corresponding codon in a natural human coronavirus genome and ii) differs by one nucleotide from a STOP codon.

Disclosed in the present invention are a short polypeptide having broad-spectrum inhibition effect on β human coronaviruses invading host cells, and the pharmaceutical use thereof. Reasonable drug design is carried out on the basis of the universality and conservation of a six-α-helix bundle (6-HB) structure of spike proteins of coronaviruses during the process of β human coronaviruses entering host cells; and α-helix conformation restriction is performed with respect to a polypeptide derived from the HR2 domain in the 6-HB, so as to provide the short polypeptide that has a broad-spectrum inhibitory effect on infections of two or more β human coronaviruses (such as SARS-CoV, MERS-CoV, SARS-CoV-2 and OC43). The polypeptide has important advantages such as strong antiviral activity, a short sequence and easy synthesis. The present invention will prospectively provide candidate drug reserve and technical reserve for research and development of drugs used for emergency prevention and control of emerging or re-emerging human coronavirus infection epidemics in the future.

The present invention concerns the use of an alpha-glucosidase glycoprotein processing inhibitor for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering an alpha-glucosidase glycoprotein processing inhibitor, such as castanospermine, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject; methods for inhibiting human coronavirus infection in a human cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing human coronavirus infection.

The invention discloses an expression vector, a cell and a vaccine of multivalent coronavirus recombinant protein and a preparation method of the multivalent coronavirus recombinant protein, and relates to the technical field of preparation of protein vaccines of coronavirus. A recombinant protein technical means is utilized to prepare a novel multivalent coronavirus recombinant protein, the novel multivalent coronavirus recombinant protein is prepared into a candidate vaccine, the candidate vaccine can induce an organism to generate immunoreactions aiming at different mutant strains of beta new coronavirus and alpha human coronavirus, and the generated immunoreactions are humoral immunity, cellular immunity and / or mucosal immunity. Therefore, the expression vector and the recombinant cell for expressing the novel multivalent coronavirus recombinant protein, provided by the invention, have a good application prospect. The vaccine containing the multivalent coronavirus recombinant protein has a wider coronavirus protection spectrum, the application range of the vaccine is expanded, and the vaccine has a good immunogenicity enhancing effect.

The invention belongs to the technical field of microbial preparation of compounds. The polyketone compound provided by the invention shows excellent inhibitory activity on influenza A virus (IAV), human coronavirus (OC43) and ZIKV (Zika virus). The polyketone compound provided by the invention has any chemical structural formula shown in the specification.

The invention provides a method for extracting and enriching phenylethanoid glycoside and lignan effective components from fructus forsythiae fresh leaves. The method comprises the following steps: extracting phenylethanoid glycoside and lignan compounds, enriching MCI resin components, analyzing by liquid chromatography-mass spectrometry, and identifying. The enrichment extracted by the method provided by the invention is a mixture containing phenylethanoid glycoside and lignan compounds respectively, and can be used as a medicine for resisting the human coronavirus HCoV-229E.